As of 2026-04-03, the Intrinsic Value of Harrow Health Inc (HROW) is 15.11 USD. This HROW valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 35.31 USD, the upside of Harrow Health Inc is -57.20%.
The range of the Intrinsic Value is 6.16 - 54.49 USD
Based on its market price of 35.31 USD and our intrinsic valuation, Harrow Health Inc (HROW) is overvalued by 57.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (43.22) - (14.08) | (19.52) | -155.3% |
| DCF (Growth 10y) | 6.16 - 54.49 | 15.11 | -57.2% |
| DCF (EBITDA 5y) | 16.69 - 69.54 | 41.33 | 17.0% |
| DCF (EBITDA 10y) | 34.72 - 137.99 | 80.58 | 128.2% |
| Fair Value | -0.69 - -0.69 | -0.69 | -101.95% |
| P/E | (2.60) - 1.20 | (0.79) | -102.2% |
| EV/EBITDA | 9.21 - 52.72 | 31.38 | -11.1% |
| EPV | (10.07) - (12.05) | (11.06) | -131.3% |
| DDM - Stable | (1.95) - (16.95) | (9.45) | -126.8% |
| DDM - Multi | 8.50 - 58.34 | 14.93 | -57.7% |
| Market Cap (mil) | 1,314.59 |
| Beta | 2.04 |
| Outstanding shares (mil) | 37.23 |
| Enterprise Value (mil) | 1,484.85 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.84% |
| Cost of Debt | 10.42% |
| WACC | 7.40% |